The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental Glomerulosclerosis (FSGS)
A Randomized,Multicentre,Prospective Study on the Tacrolimus(FK506)for Focal Segmental Glomerulosclerosis
Sponsor: Nanjing University School of Medicine
Terminated
The recruitment of subject is very difficult
Other terminated trials from Nanjing University School of Medicine
See all terminations from Nanjing University School of Medicine
Listed as NCT01451489, this NA trial focuses on FSGS and remains terminated or withdrawn. Sponsored by Nanjing University School of Medicine, it has been updated 6 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2021 — Jul 2024 [monthly]
Terminated NA
-
Jun 2018 — Jan 2021 [monthly]
Terminated NA
-
May 2017 — Jun 2018 [monthly]
Terminated NA
Status: Recruiting → Terminated
▶ Show 1 earlier version
-
Jan 2017 — May 2017 [monthly]
Recruiting NA
First recorded
Oct 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Nanjing University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .